Trials / Completed
CompletedNCT03768466
Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment
An 8-week, Prospective, Interventional, Single-arm, Multi-centre, Phase IV Study to Evaluate the Efficacy and Safety of Controlled-release Oxycodone/Naloxone (Targin®) in Moderate to Severe Low Back Pain Patients Who Are Not Adequately Controlled by NSAIDs
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Mundipharma Korea Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of the study drug (Targin®) after 8 weeks of treatment in patients with moderate to severe low back pain who are uncontrolled\* by NSAIDs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brand Name: Targin® | Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral |
Timeline
- Start date
- 2018-11-21
- Primary completion
- 2020-02-20
- Completion
- 2020-09-17
- First posted
- 2018-12-07
- Last updated
- 2021-01-25
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03768466. Inclusion in this directory is not an endorsement.